

IN THE CLAIMS:

1. (Previously Presented) A method of treating a human patient suffering from rheumatoid arthritis with a therapeutic antibody, which comprises repeated administration of a therapeutically effective amount of a human or humanized antibody expressed and glycosylated in a CHO cell expression system, to said human patient.

Claims 2-6. (Cancelled).

7. (Previously presented) The method of claim 1, wherein the antibody is administered daily for up to 30 days.

8. (Previously presented) The method of claim 7, wherein the dose of antibody is between 1 to 100 mg.

9. (Previously Presented) A method of treating a human patient suffering from rheumatoid arthritis with a therapeutic antibody, which comprises administering a therapeutically effective amount of a human or humanized antibody expressed and glycosylated in a CHO cell expression system, to said human patient, in a two-part dosing regime, wherein the antibody is administered in different doses in each part of the two-part dosing regime.

10. (Previously presented) The method of claim 9, wherein the two-part dosing regime comprises a first dosing regime, in which the antibody is administered at a dose of 1 to 5 mg for 5-10 days and a second part, in which the antibody is administered at 6-15 mg for an additional 5-10 days.

11. (Cancelled).

12. (Previously Presented) The method of claim 1, wherein said culture is grown in serum-free media.

Claims 13-14. (Cancelled).